Abiopharma

Amarin Corporation Plc (AMRN) Announces Clinical Trial Update Amarin Corporation Plc (AMRN) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: meetings, reduction
• Diseases/Conditions: our operating expenses
• Collaboration: Recordati S.p.A.
• Updated Timeline: the fourth quarter and full year 2025, the fourth quarter of 2025
  • looking statements. These forward
  • looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s quarterly report on Form 10
  • Q for the period ending September 30, 2025 and annual report on Form 10